Chapter 5: Genes and Human Diseases

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

Hello and welcome back to the Deep Dive.

Today we are taking on something massive.

We really are.

We're looking at the very blueprint of life, but specifically what happens when that blueprint has a typo or a missing page or an entire chapter ripped out.

We are digging into chapter five of the Robbins, Cautran, and Kumar pathologic basis of disease.

Genes and human diseases.

It's a heavy hitter of a chapter.

And honestly, if you work in medicine or if you just want to understand the fundamental mechanics of why bodies fail, this is the text.

It's the bridge between the microscopic and the patient in front of you.

It really is.

And I think for a lot of people genetics can feel a bit abstract.

It's a lot of letters, a lot of charts, those punnet squares from high school biology.

But our mission for today's Deep Dive is to take this off the page and look at the actual machinery.

Exactly.

We aren't just memorizing lists of syndromes here.

We are trying to understand how a single change, sometimes just one letter in a code of billions, can completely alter the shape of a human body or the function of an organ.

Right.

The core philosophy of pathology and of the Robbins text specifically is that if you understand the mechanism, how you automatically understand the morphology, which is the look, and the clinical picture.

The patient.

Yes, the patient.

We're going to traverse the whole landscape today, starting from the molecular level, those single base pairs, all the way up to massive chromosomal shifts.

And to keep us oriented, because this is incredibly dense material, the text lays out three big buckets to categorize these genetic disorders.

It gives us a framework to hang our hats on.

So first you have your monogenic disorders.

These are the Mendelian classics.

Right.

One gene, one mutation, large effect.

Think sickle cell anemia or Marfan syndrome.

High penetrance, meaning if you have the gene, you generally have the problem.

Precisely.

Then category two is chromosomal disorders.

This isn't a typo and a word.

This is a structural failure of the library itself.

You're missing a chromosome or you have an extra one.

Down syndrome is the prototype here.

And third, you have complex multigenic disorders.

These are the big ones.

Diabetes,

atherosclerosis, hypertension.

It's not one gene.

It's a polymorphism here, a variant there, plus the environment all mixing together.

But there's a fourth category, the text teases, which I found fascinating because it feels like the frontier of our understanding right now, the idea of somatic mutations.

Yes, this is becoming increasingly recognized.

These are mutations that aren't inherited from your parents.

They happen after birth in your somatic cells, your body cells.

They aren't passed down.

Right.

They stay with you.

They can lead to these strange overgrowth syndromes or predispose you to cancer.

It's a distinct category because it's acquired, not inherited.

Okay.

Let's unpack this.

We have to start at the bottom.

The mutation itself.

The text defines a mutation simply as a permanent change in DNA.

And the most critical distinction to make right out of the gate is between germline and somatic.

If a mutation is in the germline, meaning the sperm or the egg, it is transmissible.

It goes to the next generation.

Every single cell in that offspring's body will carry the change.

But if it's somatic, it dies with you.

Exactly.

It might cause a local malformation, but you don't pass it down.

Let's talk about the typos, the point mutations.

A point mutation is the substitution of a single nucleotide base, just one letter swapped for another.

And depending on what that change does to the genetic code, we give it a specific name.

If that change swaps one amino acid for another in the final protein, we call it a missense mutation.

The classic example being sickle cell.

That's the one.

You swap a single nucleotide in the beta -globin gene.

Suddenly the code calls vervaline instead of glutamic acid.

And that matters because?

Because that one tiny switch changes the hydrophobicity of the hemoglobin molecule.

It makes it sticky.

When oxygen is low, the hemoglobin clumps up, distorts the red blood cell into a sickle shape, and causes vascular occlusion.

All from one letter change.

Wow.

Then you have nonsense mutations.

Yeah.

Which sounds like the protein just starts talking gibberish.

In a way it's worse than gibberish.

A nonsense mutation changes an amino acid codon into a stop codon.

It puts a period right in the middle of the sentence.

So the protein gets cut short.

It's prematurely truncated.

And usually that means it's totally dysfunctional and gets degraded by the cell immediately.

And then there's the frame shift mutation.

This one always stressed me out when I was first learning this stuff.

It's the most chaotic because DNA is read in triplets.

Imagine a sentence made of three -letter words.

The big red dog.

If you delete just the E in the HE, the reading frame shifts.

Right, because the machinery still reads in threes.

Exactly.

Now it reads THBIGREDDOG.

It becomes complete nonsense.

Insertions or deletions that are not multiples of three throw off the entire reading frame.

Every single amino acid after that point is wrong.

It creates a completely foreign protein sequence.

But the text mentions it's not always about the coding region, right?

Yeah.

The recipe itself can be fine, but you can have mutations in the white space of the genome.

The non -coding regions, yes.

You can have a mutation in a promoter or an enhancer.

These are the volume knobs.

The gene itself is fine.

The recipe for the protein is perfect, but the instruction on how much to make is broken.

Like in thalassemias?

Exactly.

In thalassemias, you just don't make enough of the golden chain because the regulatory sequence is mutated.

So we have the types of typos.

Now let's talk about how they travel through families, the Mendelian inheritance patterns.

We have autosomal dominant, autosomal recessive, and X -linked.

I feel like we know these terms, but the Robbins text adds some really interesting nuance regarding the biology behind the patterns.

Let's start with autosomal dominant, or AD.

The key rule here is that it happens in heterozygotes.

You only need one bad copy.

If you have the mutated gene, you show the trait.

Visually, on a pedigree chart, it appears in every generation.

And structurally, what kind of proteins are usually involved in dominant disorders?

This is a great rule of thumb for anyone trying to understand pathology.

Autosomal dominant disorders usually affect structural proteins or receptors.

They rarely affect enzymes.

Why the distinction?

Why does it matter if it's a structure or an enzyme?

Think about a structural protein, like collagen or fibrillin.

If you are building a brick wall,

and 50 % of your bricks, the ones coming from the mutated gene, are crumbling, the whole wall is unstable.

Even if the other 50 % are perfectly good bricks.

Right.

The bad protein interferes with the good protein.

We call that a dominant negative effect.

You cannot mask it with the good copy.

Whereas with an enzyme… With an enzyme, usually 50 % activity is plenty.

If you are a carrier for an enzyme defect, you have half the normal amount of enzyme, but your body functions fine, you have a margin of safety.

That makes so much sense.

That's why enzyme defects are usually recessive.

You need to wipe out both copies to get 0 % activity to actually see the disease.

That is a crucial distinction.

Structural is usually dominant, enzymes are usually recessive.

But with dominant disorders, the text mentions two concepts that complicate things.

Penetrance and variable expressivity.

Let's break those down.

Penetrance is a yes or no question.

Does everyone with the gene show the disease?

If 100 people have the mutation and only 50 show symptoms, the mutation is 50 % penetrant.

It's binary.

And variable expressivity.

Variable expressivity is about the degree.

It's a dimmer switch.

You and I might both have neurofibromatosis type 1.

You might have a few café au lait spots, those coffee colored birthmarks on your skin, and be totally fine otherwise.

I might have massive tumors and skeletal deformities, same gene, same mutation, totally different expression.

And sometimes a child has a dominant disorder, but the parents are totally normal.

How does that happen?

That's a de novo mutation.

It happens spontaneously in the sperm or the egg that made the child.

The parents don't have it in their somatic cells.

This is really important for family counseling, because the risk of the next sibling having it is very low.

It was a one -off event.

But for that affected child?

They now carry the gene in every cell of their body, so the risk for their future children is 50%.

Okay, moving to autosomal recessive.

This is the largest category of Mendelian disorders.

Both alleles must be mutated.

Parents are usually carriers, meaning they are asymptomatic.

This is where you see skipped generations in the family tree.

And this is where the text brings up consanguinity.

Yes.

Because rare recessive mutations are, well, rare.

The odds of two random people carrying the exact same rare defect are extremely low.

But if those two people are related, they share ancestors.

So they are much more likely to share that same rare mutation.

And finally, X -linked.

The classic pattern.

Males are hemicygous.

We only have one X chromosome.

If that X has the mutation, we have the disease.

We don't have a backup.

Females have two X chromosomes, so they are usually carriers.

So you see this pattern where unaffected mothers pass the disease to their affected sons.

Exactly.

There are rare exceptions, like X -linked dominant disorders, such as vitamin D -resistant rickets.

But generally, it's recessive and affects males.

All right, let's get specific.

The text moves into a deep dive on defects in structural proteins.

We talked about how these are usually dominant.

The first one they highlight is a big one.

Marfan syndrome.

Marfan is fascinating because it connects a single protein defect to a massive systemic problem.

The defect is in the FBN1 gene, which encodes a protein called fibrillin 1.

Fibrillin, it sounds like a fiber.

It is.

Fibrillin acts as a scaffold.

It's like the rebar for elastin in your tissues.

Without fibrillin, your elastic tissues, like your skin, your lungs, your blood vessels, they don't have the right snapback.

They lose their elasticity.

But the text outlines a crucial insight here.

It's not just about the tissue being physically weak.

It's about a signaling molecule called TGF -beta.

This is the modern understanding of Marfan, and it's brilliant.

Normally, fibrillin has a second job.

It sequesters or hides a growth factor called TGF -beta in the extracellular matrix.

It keeps it inactive.

It puts it in a cage.

Exactly.

But in Marfan, the fibrillin is defective.

The cage is broken.

TGF -beta leaks out and runs wild.

And excessive TGF -beta signaling causes bone overgrowth and abnormal tissue remodeling.

So the tall stature, the long fingers, that's actually a result of this signaling pathway going into overdrive, not just weak tissue.

Right.

That explains the skeletal look,

the arachnidactyly, which literally means spider fingers, the pigeon breast chest deformity where the sternum protrudes or caves in.

But the scary part of Marfan isn't the fingers.

It's the heart.

It is the cardiovascular system, the aorta specifically.

Because of that lack of elastin support and the dysregulated TGF -beta signaling,

the media, the middle muscle layer of the aorta degenerates, it's called cystic medial degeneration.

So the aorta stretches under the pressure of the blood.

It stretches, it dilates, and it weakens.

The big risk is aortic dissection.

The layers of the aortic wall actually tear apart or the aorta simply ruptures.

It's a catastrophic event.

And it's the leading cause of death in these patients.

And there's an eye finding too, right?

Yes.

Ectopia lentus, bilateral subluxation of the lens.

The little suspensory ligaments that hold your lens in place inside your eye are made of fibrillin.

They snap and the lens dislocates, usually upward and outward.

If you see a patient with a dislocated lens and a dilated aorta, you have to think Marfan syndrome.

Okay, next structural disorder we need to cover.

Ehlers -Danlos syndromes, or EDS.

This is actually a group of disorders, not just one.

But the common theme connecting them all is collagen.

This is sometimes known as the contortionist disease, right?

In the popular imagination, yes.

You see hyper extensible skin, hypermobile joints.

You can pull the skin way off the body and it snaps back.

But it's incredibly fragile.

It's vulnerable to trauma.

These patients often have trouble in surgery because sutures just tear right through the tissue.

The text lists a few variants in a summary table.

Which ones are the high yield ones to know?

The classic type involves defects in type V collagen.

That's the skin and joint issues we just described.

But the most dangerous one is the vascular type.

This is a defect in type III collagen.

Why is type III so special?

Type III collagen is crucial for the structural integrity of blood vessels and hollow organs.

So these patients are at high risk for spontaneous rupture of the colon or large arteries.

It's extremely serious.

If a young person comes in with a spontaneous bowel perforation, you have to check for vascular EDS.

There's also a kyphosgoliotic type mentioned in the text.

That one is interesting from a mechanism standpoint.

Because it's not a defect in the collagen gene itself.

It's a defect in an enzyme called lysal hydroxylase that processes the collagen after it's made.

So it proves the point that you can mess up the protein or you can mess up the machine that builds the protein and get the same result.

Exactly.

The phenotype is similar weak structure, but the genetic cause is enzymatic.

Moving on from structure to reception.

Defects in receptor proteins.

The poster child here is familial hypercholesterolemia or FH.

This disease is a master class in feedback loops.

The defect here is in the gene for the LDL receptor.

Walk us through the mechanism.

How does this receptor usually work in a healthy person?

Normally your liver has these receptors on its surface that reach out and grab LDL, the bad cholesterol from the blood.

They pull it inside the liver cell, metabolize it, and clear it from circulation.

It's the body's way of keeping blood cholesterol levels in check.

In FH, those receptors are missing or broken.

So the LDL just stays in the blood?

It stays in the blood and the levels skyrocket.

But here's the real kicker.

Because the liver cells aren't getting any cholesterol inside them via those receptors, they think the body is starving for cholesterol.

Oh no.

Right.

So the liver turns on its own internal synthesis machine.

It pumps out even more cholesterol via an enzyme called HMG -CoA reductase.

That is tragic.

The blood is practically sludge, full of cholesterol.

But the liver thinks there is none, so it makes more.

It's a completely broken feedback loop.

And incidentally, this is exactly why statin drugs work.

They inhibit that enzyme, HMG -CoA reductase.

They stop the liver from making more cholesterol, forcing it to try and pull more from the blood.

And genetically, the dosage really matters here, doesn't it?

There is a huge difference.

Heterozygotes, people with one bad copy of the gene, are actually quite common, about 1 in 200 people.

They have cholesterol levels 2 to 3 times higher than normal.

They are at risk for heart attacks in adulthood, say in their 30s or 40s.

But homozygotes?

Homozygotes have two bad copies.

It's rare, but they have 5 to 6 times normal cholesterol.

They can have massive heart attacks in childhood, even at age 5 or 6.

And morphology -wise, the text mentions you see xanthomas.

Xanthomas are yellow, cholesterol -filled deposits.

You see them in the tendons, like bumps on the Achilles tendon, or on the skin, around the eyelids.

It's literally the cholesterol having nowhere else to go, so it precipitates out into the tissues.

All right, let's get into the heavy stuff.

Section 4.

Disorders associated with enzyme defects.

We said earlier these are usually recessive.

The text focuses heavily on lysosomal storage diseases.

The concept here is simple, but devastating.

The lysosome is the cell's stomach.

It's the recycling center.

It contains specific enzymes to break down big, complex molecules.

If just one of those enzymes is missing, the specific molecule it's supposed to break down, the substrate doesn't get broken down.

It just sits there.

It piles up.

It piles up.

The lysosome swells, the cell swells, and eventually the cell dies or malfunctions.

And depending on where that substrate is usually found in the body, different organs get hit.

Let's start with Tay -Sachs disease.

This is a GM2 gangliosidosis.

The missing enzyme is hexosaminidase A.

The substrate that piles up is GM2 ganglioside.

And where do gangliosides normally live?

Mostly in neurons.

So this is a severe disease of the central nervous system.

The neurons literally balloon up with these storage vacuoles filled with gangliosides.

The text mentions a specific look under the electron microscope for this.

World configurations.

It looks like onion skin layers of membranes packed inside the lysosome.

And the classic clinical sign you read about is the cherry red spot.

This is a board exam classic, but it makes total anatomical sense if you think about it.

You look into the patient's eye with an ophthalmoscope.

The retina is swollen and pale because the ganglion cells are stuffed with lipid.

But the fovea, the very center of the retina, doesn't have those ganglion cells over it.

It's very thin.

So you can see the normal red blood vessels underneath.

Exactly.

You see the red chloride underneath.

That contrast, the red center against the pale swollen surrounding retina, creates the cherry red spot.

And sadly, the clinical course for Tay -Sachs is brutal.

It is.

The infants appear normal at birth, but by six months, motor deterioration sets in.

Blindness, severe seizures, and death, usually by age two or three.

It's highly prevalent in Ashkenazi Jewish populations due to a founder effect and high carrier frequency.

Next on the list is Neiman -Pick disease.

Specifically, types A and B.

The deficient enzyme here is sphingomyelinase.

So naturally, you accumulate sphingomyelin.

And the cells here look different than in Tay -Sachs.

They become these massive foamy macrophages.

Under the electron microscope, instead of onion skins, you see zebra bodies, which are these laminated, striped inclusions.

What's the clinical difference between type A and type B?

Type A is the severe infant form.

It involves the central nervous system, severe neurological damage, massive organ enlargement, and death in early childhood.

Type B is the body type.

You get organ enlargement, a huge liver and spleen, but no CNS involvement.

They can survive into adulthood.

And the text throws a curveball with Neiman -Pick type C.

Type C is totally different.

It's named Neiman -Pick, but it's not actually an enzyme defect.

It's a defect in cholesterol trafficking.

How does that work?

The genes Nbc1 and Nbc2 act like traffic cops for cholesterol moving out of the lysosome.

If those genes are broken, the cholesterol gets stuck inside.

It presents with progressive neurologic damage or, in fetuses, something called high drops fetalis, which is massive fluid accumulation.

OK, moving on to goucher disease.

This is the most common lysosomal storage disease.

The deficiency is in an enzyme called glucocerebrusidase.

And the hallmark here is the goucher cell.

I love the visual description of this cell.

In the text, it's a macrophage, but the cytoplasm looks like crumpled tissue paper.

It's fibrillary, not just foamy, like in Neiman -Pick.

And where do these crumpled paper cells go?

What do they damage?

They stuff the spleen, the liver, and the bone marrow.

The spleen can get incredibly massive, but the bone marrow involvement is key.

It erodes the bone, causing severe bone pain and pathologic fractures.

It also crowds out the normal blood -making cells.

So you get pancytopenia, low red cells, low white cells, low platelets.

The text also mentions a really interesting link to another major disease.

Parkinson disease.

There is a strong proven link between carrying goucher mutations and the development of Parkinson's later in life.

We are still working out the exact mechanism, but the connection is undeniable.

But there is some good news with goucher, right, in terms of treatment?

Yes.

Because this disease primarily affects macrophages, we can treat it with enzyme replacement therapy.

You infuse the missing synthetic enzyme into the patient's blood.

The macrophages literally eat it up, and it clears the storage from the lysosomes.

It's one of the great success stories in genetics.

Let's round out the lysosomes with the mucopolysaccharidosis, or MPS.

These are defects in the enzymes that break down GAGS glycosaminoglycans, things like germatin sulfate or heparin sulfate.

These are the lubricants and structural components of the extracellular matrix, ground substance.

The two big ones to know are Hurler syndrome and Hunter syndrome.

Hurler, which is MPSI, is the severe form.

You see what used to be called gargoyalism, very coarse facial features.

You see corneal clouding where the eyes get milky and dangerous coronary artery buildup.

Death usually happens in childhood.

And Hunter, MPS2.

Hunter is X -linked, which makes it unique among these mostly recessive diseases.

It's generally milder.

And the absolute key clinical distinction,

no corneal clouding.

Hunters can see clearly.

That's the classic mnemonic students use to remember the difference.

That covers the lysosomes.

But the cell also stores energy as glycogen.

If you can't access that energy, you get glycogen storage diseases.

Right, glycogenosis.

And the symptoms depend entirely on where the enzyme is missing.

Is the blockage in the liver or is it in the muscles?

The text classifies them by location.

Let's do the hepatic type first.

This is von Gehrig disease, or type I.

The liver lacks glucose 6 -phosphatase.

This enzyme is the exit door for glucose.

Without it, the liver can break down its stored glycogen, but it cannot release the final free glucose into the blood.

So the liver gets huge, stuffed with all this trapped glycogen.

Hepatomegaly.

And the blood sugar crashes.

Because the liver can't do its main job of maintaining blood glucose between meals, these patients suffer from severe hypoglycemia.

Then you have the myopathic type.

McCartal disease, type V.

The defect is in muscle phosphorylase.

Here, the liver is totally fine.

But the muscles cannot break down their own glycogen fuel during exercise.

So you get muscle cramps.

Extremely painful cramps.

And there's a classic clinical test for this.

If you make the patient exercise, their blood lactate levels do not rise.

Normally, intense exercise produces lactate from glycolysis.

Here, the pathway is blocked at the source, so no laxate is produced.

And finally, the generalized type, Pomp disease.

PompTep2 is a bit of a trick.

It is a glycogen storage disease.

But the missing enzyme acid maltase, or acid alpha glucosidase, is actually a lysosomal enzyme.

So the glycogen piles up inside the lysosomes, not just in the general cytoplasm.

And the main target organ.

The heart.

You get massive cardiomegaly.

The heart muscle gets completely stuffed with glycogen and fails.

It's a major cause of fatal heart failure in infants.

We are moving fast, but we have to hit section five.

Disorders of epigenetic machinery.

This is a newer field of pathology.

It's not about the DNA code being wrong.

It's about the readers and writers.

Exactly.

The genetic code is fine, but the bookmarks and the highlighters are messed up.

It's about how genes are turned on and off.

Rett syndrome is the key example the text provides here.

And this affects females almost exclusively.

It does.

It's an X -linked dominant mutation in the MECP2 gene.

For males who only have one X chromosome, this mutation is usually lethal in utero.

Females survive because they have a backup X, although the defective one causes the disease.

And the clinical picture is just heartbreaking.

They develop normally for the first year or two of life.

Then rapid regression sets in.

They lose the language they just learned.

They lose motor skills.

And they develop these characteristic, repetitive, hand -wringing movements.

It's fundamentally a defect in chromatin regulation, how the genes are managed in the developing brain.

Okay.

Let's zoom way out.

We've been talking about gene single pages or words in the book.

Now let's talk about the whole library.

Section 6, chromosomal disorders.

The big picture.

Visualizing the 46 chromosomes through a karyotype.

We have the P arm, which stands for petite or the short arm, and the Q arm, which is the long arm.

Structural abnormalities first.

We can have translocations.

Swapping pieces between two different chromosomes or deletions where you lose a chunk of a chromosome, or isochromosomes where the chromosome divides horizontally during cell division instead of vertically, giving you a weird chromosome with two P arms or two Q arms.

Let's talk about the big cited genetic disorders.

Trisomy 21, Down syndrome.

The most common chromosomal disorder, it's usually caused by meiotic non -disjunction.

The chromosome pair just fails to separate properly during meiosis, usually in the mother.

And we know there is a strong correlation with increasing maternal age.

But the text specifically mentions a hereditary form too.

The Robertsonian translocation.

This is highly testable and clinically crucial.

If a young mother, say in her 20s, has a baby with Down syndrome, you have to check her chromosomes.

She might carry a balanced translocation.

It means, for example, her chromosome 21 is physically stuck to her chromosome 14.

She has the normal amount of genetic material, so she's perfectly healthy.

But when she makes eggs, that stuck chromosome gets passed on, predisposing her to having more affected children.

It's not just bad luck like non -disjunction.

Trisomy 21.

Flat facial profile, a single semi -increase on the palm, and major congenital heart defects, specifically AV canal defects.

But there's also an interesting gene dosage effect the text points out.

Chromosome 21 carries the APP gene.

Amyloid precursor protein.

Right.

So patients with Down syndrome have three copies of the APP gene instead of two.

This leads to excess amyloid production, which causes early onset Alzheimer's disease, often by the time they reach their 40s.

Another chromosomal deletion mentioned is 22Q11 .2.

Also known as deGeorge syndrome or Velo -cardiofacial syndrome, the classic mnemonic to remember the features is CTCH22.

Partiac defects, abnormal facies, thymicoplasia, cleft palate, hypocalcemia.

The thymicoplasia means they have no thymus, leading to severe T -cell immunodeficiency.

The hypocalcemia comes from parathyroid gland issues.

And crucially, this dilution is too small to see on a standard karyotype.

You need a specialized test called FESH fluorescence in situ hybridization to actually diagnose it.

Moving to sex chromosome disorders.

Klinefelter syndrome.

47, XXY.

A male phenotype, but with an extra X chromosome.

That extra X heavily interferes with normal male development.

They have hypogonadism atrophic small tests.

They are typically very tall.

They often have gynecomastia or breast development.

And it's a major, major cause of male infertility.

And Turner syndrome.

45X.

Total or partial loss of the second sex chromosome.

These are phenotypic females.

They are characteristically short in stature.

They often have a webbed neck.

Where does the webbing come from?

It actually comes from a cystic hygroma, a large lymph sac that forms in the neck in utero.

The sac eventually resolves, but it leaves behind excess stretched skin, which creates the webbing.

They also have streak ovaries, meaning they are infertile, and a specific congenital heart defect called coercation of the aorta.

The text notes that many Turner patients are actually mosaics.

Right, 45X, 46XX.

Some cells have the normal count, some don't.

Severity of the symptoms depends entirely on the proportion of normal cells in their body.

Okay, Section 7.

Single gene disorders with non -classic inheritance.

These are the rule breakers.

First up, trinucleotide repeat mutations.

This is a fascinating mechanism.

You have a sequence of three nucleotides, like CGG, that naturally repeats a few times in the DNA.

Normal people have maybe 10 or 20 repeats.

But in these diseases, the repeats are unstable.

They expand during game to genesis.

They get longer and longer with each generation.

Fragile X syndrome is the prototype.

The repeat is CGG, and it's located in the FMR1 gene.

What does the expansion actually do to the gene?

When the repeat gets too long, it causes hypermethylation of the gene.

It effectively silences it.

The gene is shut off, so no FMR1 protein is made.

And this is the second most common genetic cause of intellectual disability after Down syndrome, right?

The physical phenotype includes a long face, a large mandible, and macro -orchidism, which means large tests.

The text mentions a concept here called anticipation.

Anticipation is the clinical observation that the disease gets worse or appears at an earlier age in subsequent generations.

This happens because the repeats physically get longer every time they are passed down.

In Fragile X, the massive expansion happens specifically during eugenesis when the mother passes it on to the child.

But there is a clinical twist with the grandfathers of these children.

Yes, the premutation carriers.

Grandfathers can have a premutation.

Not enough repeats to have full -blown Fragile X and silencing, but enough to cause a completely different problem later in life called FXTAS Fragile X -Associated Tremorotaxia Syndrome.

This isn't from silencing.

It's actually a toxic effect of the mutant mRNA itself.

And the other big repeat disease is Huntington disease.

Here, the repeat is CAG.

CAG codes for the amino acid glutamine, so you get a polyglutamine tract in the final protein.

This creates a toxic, misfolded protein that aggregates and kills neurons.

It's a toxic gain of function.

And unlike Fragile X, the expansion here usually happens during spermatogenesis paternal transmission.

Next rule breaker,

mitochondrial mutations.

Labor Hereditary Optic Neuropathy, or LHON, is the example.

It causes progressive blindness.

The key mechanism to understand here is the inheritance pattern.

Mitochondria only come from the egg, never the sperm, so inheritance is strictly maternal.

So an affected mother passes it to all her children?

All of them.

And an affected father passes it to none of them.

Genomic imprinting.

This concept really blew my mind the first time I learned it.

It completely changes the way we think about Mendelian inheritance.

We usually think mom's copy and dad's copy of a gene are functionally equal.

In imprinting, one parent's copy is permanently stamped OUPF via methylation.

It's naturally silenced.

The classic example is the Prader -Willi and Angelman specific region on chromosome 15.

Right.

Region 15Q12.

In this specific region of the genome, some genes are only supposed to be active on the chromosome you got from dad, and some are only active on the chromosome you got from mom.

So what happens if you have a deletion on the paternal chromosome?

If you delete dad's copy, you lose the genes that only dad is supposed to provide.

Mom's copies are physically there, but they are imprinted, they are silenced.

So you have zero functional copies.

This gives you Prader -Willi syndrome.

The result is profound hypotonia, hypogonadism, and an insatiable appetite leading to severe obesity.

And if you have the exact same physical deletion, but on the maternal chromosome… You lose the genes that only mom provides.

Dad's copy is present but silenced.

You get Angelman syndrome.

It's a totally different disease.

You see the happy puppet presentation, ataxia, seizures, and inappropriate, unprovoked laughter.

Same exact deleted region of DNA.

Totally different disease.

Entirely dependent on which parent gave you the deletion.

That is wild to think about.

And finally in this section.

Gornadal mosaicism.

This solves a classic medical mystery.

Two phenotypically normal parents have a child with a highly penetrant autosomal dominant disease like osteogenesis imperfecta.

You think, okay, it's a new de novo mutation in the child, but then they have a second child with the exact same disease.

Which is statistically impossible for two independent de novo mutations.

Exactly.

The answer is that one parent has the mutation only in their germ cells.

Their sperm or egg precursors.

Their somatic cells, their body cells, are totally normal, so they look and function normally.

But they keep passing the mutation on.

We are in the homestretch here.

Section 8.

Somatic mosaicism and molecular diagnosis.

We touched on somatic mosaicism at the very start of the deep dive.

These are mutations occurring after zygote formation.

The text mentions overgrowth syndromes as the main example.

Syndromes like proteus syndrome or CLOVs.

These are caused by activating mutations in the PI3KKT growth pathway.

The fascinating question is why are they mosaic?

Because if they were germline mutations, meaning they were in every single cell of the fetus, the fetus wouldn't survive.

It would be lethal in utero.

It's only compatible with life because it's mosaic.

Some cells are normal, which keeps the body functioning while the mutated cells cause the overgrowth.

And finally, the toolkit.

Molecular diagnosis.

How do we actually see these things?

The text outlines a few core technologies.

Faceage, as we mentioned earlier, uses fluorescently colored probes to spot microdeletions like the 22Q deletion or translocations right on the chromosome.

Array CGH.

Or a comparative genomic hybridization.

This checks for copy number variations.

It looks across the whole genome to see if you have too much or too little DNA at any specific locus.

Next generation sequencing or NGS.

This is the workhorse now.

Rapid massive parallel sequencing of specific gene panels or entire whole genomes to find point mutations or small indoles.

And liquid biopsy.

This is the future of oncology.

Detecting circulating tumor DNA or CT DNA in a simple blood draw.

It allows us to monitor cancer mutations and tumor dynamics without invasive tissue surgery.

Wow.

We made it.

From a single letter change causing sickle cell anemia to the visible massive chromosomal shifts in Down syndrome.

It is quite a journey through the text.

So synthesizing all of this chapter, what does this all mean for the student or the practitioner?

For me, the big takeaway is that pathology isn't just about memorizing endless lists of symptoms and eponyms.

It's about understanding the mechanism.

If you understand the gene defect, the missing enzyme, the broken structural scaffold, the silenced chromosome, you can predict the cellular changes.

And if you know the cellular changes, you can understand exactly why the patient has their specific symptoms.

The mechanism explains the patient.

That is a great place to end it.

It really bridges the gap between the lab bench and the bedside.

Before we go, here's a thought for you to mull over.

If epigenetic tags like methylation can silence genes and diseases like Fragile X or Prader -Willi, what happens when we develop the pharmacology to just erase those tags?

Could we reverse inheritance?

Think about that.

Stay curious, everyone.

Keep connecting the dots.

This has been the Last Minute Lecture Team.

Thanks for joining this deep dive into the genetic basis of disease.